-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3175 Flumatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: An Open-Label, Multi-Center Study

Program: Oral and Poster Abstracts
Session: 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, clinical trials, Clinical Research
Sunday, December 10, 2023, 6:00 PM-8:00 PM

Ziyu Wen1*, Ying Zhao2*, Guowei Li3*, YongZhong Su4*, FeiHeng Chen4*, HongFang Tao4*, ZhengJin Zheng5*, Wuqiang Lin6*, XiuLi Chen6*, Meili Meng7*, Lian Yu8*, LongTian Chen8*, JianQing Huang8*, Guocai Wu9*, Mengxia Zhao10*, Zhenfang Liu, MD11*, Hongqian Zhu12*, Yirong Jiang10*, Qifa Liu, MD13, Xiaoli Liu14* and Na Xu14*

1Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, AL, China
2Department of Hematology, The First People’s Hospital of Foshan, Foshan, China
3Department of Hematology, Huizhou Municipal Central Hospital, Huizhou, China
4Department of Hematology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China
5Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, China
6Department of Hematology, The First Hospital of Putian City, Putian, China
7Department of Hematology, Ganzhou People’s Hospital, Ganzhou, China
8Department of Hematology, Longyan First Hospital Affiliated Fujian Medical University, Longyan, China
9Department of Hematology, Central People’s Hospital of Zhanjiang, Zhanjiang, China
10Department of Hematology, Dongguan Hospital Affiliated to Southern Medical University, Dongguan, China
11Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
12Department of Hematology, Guizhou Provincial People’s Hospital, Guiyang, China
13Nanfang Hospital, Southern Medical University, Guangzhou, China
14Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China

Background Tyrosine kinase inhibitors (TKIs) ushered in the era of targeted therapy for chronic myeloid leukemia(CML), which greatly improved the prognosis of patients with CML. Flumatinib is a second-generation tyrosine kinase inhibitor (TKI), which is currently approved for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in China. And some current clinical trials revealed that flumatinib has been shown to be a more potent inhibitor of BCR::ABL than imatinib.

Methods In this open label, single-arm, multicenter study, 127 patients with newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) treated with flumatinib were enrolled. The primary endpoint of this study was early molecular response (EMR) rates at 3 months. The secondary were the rates of complete cytogenic response (CCyR), major molecular response (MMR) at 3, 6, 12 months and treatment-related adverse events (AEs). The trial is registered with ClinicalTrials.gov NCT04591197.

Results From October 2020 to December 2022, a total of 158 patients with CP-CML were assessed for eligibility, of whom 127 were followed up for more than 3 months. 79(62%) patients were men and 48 (38%) were women. The median age was 47 years (range, 19-82 years), The median time from diagnosis to treatment was 6 days (0-176 days) and the median follow-up was 9.7 months (range 3.1-26.6 months). Of evaluable 127 patients, EMR was achieved by 85% (95% confidence interval [CI], 77.6%-90.7%) of patients at 3 months. After the initiation of flumatinib treatment, the incidence of MMR at 3, 6, and 12 months was 24%, 59%, and 73%, respectively. Patients receiving flumatinib had higher rates of CCyR at 6 months and MMR 12 months than the data from DASISION (dasatinib) and ENESTnd (nilotinib) therapy (85% vs 73% vs 67% and 73% vs 46% vs 44%). Progression-free survival (PFS) rate at 1-year was 97.2%. Diarrhea (34%) were the most commonly reported adverse events. Most treatment-related adverse events were grade 1/2. None of the patients discontinued or died due to AEs.

Conclusion Flumatinib as first-line therapy in patients with newly diagnosed CP-CML was not inferior to nilotinib and dasatinib and well tolerated.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH